CS5001-101
12 Apr 2022
Trial Summary
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Acronym:
CS5001-101
ACTRN/NCT /ethics:
NCT05279300
Scientific title:
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Sponsor / Cooperative group:
Cstone
Trial & Patient Characteristics
| Cancer Type | All cancers; Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2022-03-28 |
| Anticipated End Date | 2024-03-31 |
Participating Hospitals
| Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| Sue.Yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Sarwan Bishnoi |
| Recruitment Status | Recruiting |